Chiesi Farmaceutici SpA (Chiesi) develops and commercializes innovative therapeutic products. The company offers drug delivery equipment with marketing and sales offices across Europe.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Chiesi has undertaken several R&D initiatives focused on innovation and technological advancements. The company emphasizes the development of cutting-edge therapies and enhancing positive outcomes for patients. Chiesi's R&D efforts are concentrated on three main business areas: AIR (respiratory diseases), RARE (rare and ultra-rare diseases), and CARE (Neonatology, Special Care, and Consumer Healthcare). The company is expanding its range of products with different types of drugs, including biological products and advanced therapies, to address unmet medical needs. Chiesi is committed to clinical trial transparency and data sharing, and it has launched a public clinical research platform to raise awareness about ongoing and completed clinical studies. The company also focuses on decentralized clinical trials and has established the DANCE initiative to enhance the clinical trial journey for participants. Additionally, Chiesi has opened a Biotech Center of Excellence in Parma, Italy, to focus on the development and production of biologic drugs. The company has seven major research centers located in Parma (Italy), Paris (France), Chippenham (UK), Cary (USA), Lidingo (Sweden), Shanghai (China), and Toronto (Canada). The company has achieved 5,529 patents worldwide and filed 33 patent applications with the European Patent Office in 2024. Chiesi has a strong pipeline focused on respiratory, rare diseases, neonatology, and special care. The company has formed a major technology alliance with Gossamer Bio to develop treatments for pulmonary arterial hypertension and related lung conditions. In FY2024, the company spent EUR829 million on its R&D activities, which as a percentage of revenue stood at 24.3% which grew 15% YoY.